{
  "hash": "5f7470682749f54d7ace327de09b0749",
  "result": {
    "markdown": "---\ntitle: \"Systematic review and meta-analysis of Real-World Evidence\"\nauthors:   \n  - name: Dimitris Mavridis\n    affiliations:\n      - ref: ioannina\n  - name: Thomas Debray\n    orcid: 0000-0002-1790-2719\n    affiliations:\n      - ref: smartdas\naffiliations:\n  - id: smartdas\n    name: Smart Data Analysis and Statistics B.V.\n    city: Utrecht\n  - id: ioannina\n    name: University of Ioannina\n    city: Ioannina\nformat:\n  html:\n    toc: true\n    number-sections: true\nexecute:\n  cache: true\nbibliography: 'https://api.citedrive.com/bib/0d25b38b-db8f-43c4-b934-f4e2f3bd655a/references.bib?x=eyJpZCI6ICIwZDI1YjM4Yi1kYjhmLTQzYzQtYjkzNC1mNGUyZjNiZDY1NWEiLCAidXNlciI6ICIyNTA2IiwgInNpZ25hdHVyZSI6ICI0MGFkYjZhMzYyYWE5Y2U0MjQ2NWE2ZTQzNjlhMWY3NTk5MzhhNzUxZDNjYWIxNDlmYjM4NDgwOTYzMzY5YzFlIn0=/bibliography.bib'\n---\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-1_ba531256ba5161c294d52b2c63cbe000'}\n\n:::\n\n\n## Introduction\n\nWe first load the required packages\n\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-2_687af4d7dc1ee383fa1bbf5d9274e104'}\n\n```{.r .cell-code}\nlibrary(dplyr)\nlibrary(netmeta)\n```\n:::\n\n\n\n\n## Advanced Therapies for Ulcerative Colitis\nIn this example, we consider a systematic literature review of Phase 3 \nrandomized controlled trials investigating the following advanced therapies: \ninfliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, \nfilgotinib, ozanimod, and upadacitinib [@panaccione_efficacy_2023]. This review \nincluded 48 RCTs, from which 23 were found eligible for inclusion in a \nnetwork meta-analysis. \n\nThe included RCT populations were largely comparable in their baseline\ncharacteristics, though some heterogeneity was noted in weight, \ndisease duration, extent of disease, and concomitant medications. \nA risk of bias assessment showed a low risk of bias for all included RCTs, \nwhich were all industry sponsored.\n\n### Example Dataset\nWe here focus on the synthesis of 18 trials that contributed efficacy data for \ninduction in bio-naive populations. The following FDA- and/or EMA-approved \nbiologic or SMD doses were investigated: \n\n* Adalimumab subcutaneous 160 mg at week 0, 80 mg at week 2, and 40 mg at week 4 (`ADA160/80`)\n* Infliximab intravenous 5 mg/kg (`INF5`) at weeks 0, 2, and 6 then every 8 weeks\n* Infliximab intravenous 10 mg/kg (`INF10`) at weeks 0, 2, and 6 then every 8 weeks\n* Filgotinib oral 100 mg once daily (`FIL100`)\n* Filgotinib oral 200 mg once daily (`FIL200`)\n* Golimumab subcutaneous 200 mg at week 0 and 100 mg at week 2 (`GOL200/100`)\n* Ozanimod oral 0.23 mg once daily for 4 days, 0.46 mg once daily for 3 days, then 0.92 mg once daily (`OZA0.92`)\n* Tofacitinib oral 10 mg twice daily for 8 weeks (`TOF10`)\n* Upadacitinib oral 45 mg once daily for 8 weeks (`UPA45`)\n* Ustekinumab intravenous 6 mg/kg at week 0 (`UST6`)\n* Vedolizumab intravenous 300 mg at weeks 0, 2, and 6 (`VED300`)\n\nThe reference treatment is placebo (`PBO`).\n\n\n\n::: {.cell tbl-cap='Efficacy outcomes (i.e., clinical remission) data of induction bio-na√Øve populations' hash='chapter_10_cache/html/unnamed-chunk-3_9c23db7041279ca4da9d5ed69c88f02c'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> studlab </th>\n   <th style=\"text-align:right;\"> treat1 </th>\n   <th style=\"text-align:right;\"> treat2 </th>\n   <th style=\"text-align:right;\"> event1 </th>\n   <th style=\"text-align:right;\"> n1 </th>\n   <th style=\"text-align:right;\"> event2 </th>\n   <th style=\"text-align:right;\"> n2 </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-1 </td>\n   <td style=\"text-align:right;\"> INF10 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> 39 </td>\n   <td style=\"text-align:right;\"> 122 </td>\n   <td style=\"text-align:right;\"> 47 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-1 </td>\n   <td style=\"text-align:right;\"> INF10 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 39 </td>\n   <td style=\"text-align:right;\"> 122 </td>\n   <td style=\"text-align:right;\"> 18 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-1 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 47 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n   <td style=\"text-align:right;\"> 18 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-2 </td>\n   <td style=\"text-align:right;\"> INF10 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> 33 </td>\n   <td style=\"text-align:right;\"> 120 </td>\n   <td style=\"text-align:right;\"> 41 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-2 </td>\n   <td style=\"text-align:right;\"> INF10 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 33 </td>\n   <td style=\"text-align:right;\"> 120 </td>\n   <td style=\"text-align:right;\"> 7 </td>\n   <td style=\"text-align:right;\"> 123 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ACT-2 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 41 </td>\n   <td style=\"text-align:right;\"> 121 </td>\n   <td style=\"text-align:right;\"> 7 </td>\n   <td style=\"text-align:right;\"> 123 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> GEMINI 1 </td>\n   <td style=\"text-align:right;\"> VED300 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 30 </td>\n   <td style=\"text-align:right;\"> 130 </td>\n   <td style=\"text-align:right;\"> 5 </td>\n   <td style=\"text-align:right;\"> 76 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Japic CTI-060298 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 21 </td>\n   <td style=\"text-align:right;\"> 104 </td>\n   <td style=\"text-align:right;\"> 11 </td>\n   <td style=\"text-align:right;\"> 104 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Jiang 2015 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 22 </td>\n   <td style=\"text-align:right;\"> 41 </td>\n   <td style=\"text-align:right;\"> 9 </td>\n   <td style=\"text-align:right;\"> 41 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> M10-447 </td>\n   <td style=\"text-align:right;\"> ADA160/80 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 9 </td>\n   <td style=\"text-align:right;\"> 90 </td>\n   <td style=\"text-align:right;\"> 11 </td>\n   <td style=\"text-align:right;\"> 96 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> NCT01551290 </td>\n   <td style=\"text-align:right;\"> INF5 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 11 </td>\n   <td style=\"text-align:right;\"> 50 </td>\n   <td style=\"text-align:right;\"> 5 </td>\n   <td style=\"text-align:right;\"> 49 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> NCT02039505 </td>\n   <td style=\"text-align:right;\"> VED300 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 22 </td>\n   <td style=\"text-align:right;\"> 79 </td>\n   <td style=\"text-align:right;\"> 6 </td>\n   <td style=\"text-align:right;\"> 41 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> OCTAVE 1 </td>\n   <td style=\"text-align:right;\"> TOF10 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 56 </td>\n   <td style=\"text-align:right;\"> 222 </td>\n   <td style=\"text-align:right;\"> 9 </td>\n   <td style=\"text-align:right;\"> 57 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> OCTAVE 2 </td>\n   <td style=\"text-align:right;\"> TOF10 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 43 </td>\n   <td style=\"text-align:right;\"> 195 </td>\n   <td style=\"text-align:right;\"> 4 </td>\n   <td style=\"text-align:right;\"> 47 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> PURSUIT-SC </td>\n   <td style=\"text-align:right;\"> GOL200/100 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 45 </td>\n   <td style=\"text-align:right;\"> 253 </td>\n   <td style=\"text-align:right;\"> 16 </td>\n   <td style=\"text-align:right;\"> 251 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> SELECTION </td>\n   <td style=\"text-align:right;\"> FIL100 </td>\n   <td style=\"text-align:right;\"> FIL200 </td>\n   <td style=\"text-align:right;\"> 47 </td>\n   <td style=\"text-align:right;\"> 277 </td>\n   <td style=\"text-align:right;\"> 60 </td>\n   <td style=\"text-align:right;\"> 245 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> SELECTION </td>\n   <td style=\"text-align:right;\"> FIL100 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 47 </td>\n   <td style=\"text-align:right;\"> 277 </td>\n   <td style=\"text-align:right;\"> 17 </td>\n   <td style=\"text-align:right;\"> 137 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> SELECTION </td>\n   <td style=\"text-align:right;\"> FIL200 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 60 </td>\n   <td style=\"text-align:right;\"> 245 </td>\n   <td style=\"text-align:right;\"> 17 </td>\n   <td style=\"text-align:right;\"> 137 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> TRUE NORTH </td>\n   <td style=\"text-align:right;\"> OZA0.92 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 66 </td>\n   <td style=\"text-align:right;\"> 299 </td>\n   <td style=\"text-align:right;\"> 10 </td>\n   <td style=\"text-align:right;\"> 151 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> U-ACCOMPLISH </td>\n   <td style=\"text-align:right;\"> UPA45 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 54 </td>\n   <td style=\"text-align:right;\"> 166 </td>\n   <td style=\"text-align:right;\"> 3 </td>\n   <td style=\"text-align:right;\"> 81 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> U-ACHIEVE Study 2 </td>\n   <td style=\"text-align:right;\"> UPA45 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 41 </td>\n   <td style=\"text-align:right;\"> 145 </td>\n   <td style=\"text-align:right;\"> 4 </td>\n   <td style=\"text-align:right;\"> 72 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ULTRA-1 </td>\n   <td style=\"text-align:right;\"> ADA160/80 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 24 </td>\n   <td style=\"text-align:right;\"> 130 </td>\n   <td style=\"text-align:right;\"> 12 </td>\n   <td style=\"text-align:right;\"> 130 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ULTRA-2 </td>\n   <td style=\"text-align:right;\"> ADA160/80 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 32 </td>\n   <td style=\"text-align:right;\"> 150 </td>\n   <td style=\"text-align:right;\"> 16 </td>\n   <td style=\"text-align:right;\"> 145 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> UNIFI </td>\n   <td style=\"text-align:right;\"> UST6 </td>\n   <td style=\"text-align:right;\"> PBO </td>\n   <td style=\"text-align:right;\"> 27 </td>\n   <td style=\"text-align:right;\"> 147 </td>\n   <td style=\"text-align:right;\"> 15 </td>\n   <td style=\"text-align:right;\"> 151 </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\nThe corresponding network is displayed below:\n\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-4_f0a92d7385e2bbc41332a55c7a54c96b'}\n::: {.cell-output-display}\n![Evidence network of 18 trials that contributed efficacy data for induction in bio-naive populations](chapter_10_files/figure-html/unnamed-chunk-4-1.png){width=960}\n:::\n:::\n\n\n### Network meta-analysis\nBelow, we conduct a random effects network meta-analysis of the reported study \neffects (expressed as odds ratio) and consider placebo (`treat = \"PBO\"`) as \nthe control treatment.\n\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-5_b14ff4ed37c822e51841370713a292d1'}\n\n```{.r .cell-code}\nNMA.uc <- netmeta(TE = TE, seTE = seTE, treat1 = treat1, treat2 = treat2,\n                  studlab = studlab, data = UlcerativeColitis, sm = \"OR\", \n                  ref = \"PBO\", comb.random = TRUE)\n```\n:::\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-6_2bff19fe8eb4be9362ca97aca96fb111'}\n::: {.cell-output-display}\n![](chapter_10_files/figure-html/unnamed-chunk-6-1.png){width=672}\n:::\n:::\n\n\nAll treatments except `FIL100` and `UST6` are significantly more efficacious than \n`PBO` at inducing clinical remission. We can now estimate the probabilities of each treatment being at each possible rank and the SUCRAs (Surface Under the Cumulative RAnking curve):\n\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-7_08d229dba331acce03815c91e7c5f5d4'}\n\n```{.r .cell-code}\nsucra.uc <- rankogram(NMA.uc, nsim = 100, random = TRUE, common = FALSE, \n                      small.values = \"undesirable\")\n\n# Exctract the SUCRA values\nsucra.uc$ranking.random\n```\n\n::: {.cell-output .cell-output-stdout}\n```\n ADA160/80     FIL100     FIL200 GOL200/100      INF10       INF5    OZA0.92 \n0.28818182 0.18363636 0.45909091 0.61727273 0.58181818 0.75727273 0.73000000 \n       PBO      TOF10      UPA45       UST6     VED300 \n0.01545455 0.37000000 0.98181818 0.36636364 0.64909091 \n```\n:::\n:::\n\n\nThese results indicate that 98.2% of evaluated treatments are worse than `UPA45`.\n\n\n\n## COVID-19\n\n### Example Dataset\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-8_85909eebf794f09e56bb5bcc7c37181b'}\n\n:::\n\n\nWe have the following treatments: standard care (`treat = \"STD\"`), ...\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-9_fe6398e09b440d4d7dfec31394a5f2f4'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> studlab </th>\n   <th style=\"text-align:right;\"> treat1 </th>\n   <th style=\"text-align:right;\"> treat2 </th>\n   <th style=\"text-align:right;\"> event1 </th>\n   <th style=\"text-align:right;\"> n1 </th>\n   <th style=\"text-align:right;\"> event2 </th>\n   <th style=\"text-align:right;\"> n2 </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;\"> Abd-Elsalam et al </td>\n   <td style=\"text-align:right;\"> HCQ </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 6 </td>\n   <td style=\"text-align:right;\"> 97 </td>\n   <td style=\"text-align:right;\"> 5 </td>\n   <td style=\"text-align:right;\"> 97 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Biegel et al </td>\n   <td style=\"text-align:right;\"> REM </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 59 </td>\n   <td style=\"text-align:right;\"> 541 </td>\n   <td style=\"text-align:right;\"> 77 </td>\n   <td style=\"text-align:right;\"> 521 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Cao et al </td>\n   <td style=\"text-align:right;\"> LOP+RIT </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 19 </td>\n   <td style=\"text-align:right;\"> 99 </td>\n   <td style=\"text-align:right;\"> 25 </td>\n   <td style=\"text-align:right;\"> 100 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Cavalcanti et al </td>\n   <td style=\"text-align:right;\"> HCQ </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 1 </td>\n   <td style=\"text-align:right;\"> 221 </td>\n   <td style=\"text-align:right;\"> 1 </td>\n   <td style=\"text-align:right;\"> 227 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Davoudi-Monfared </td>\n   <td style=\"text-align:right;\"> INT-B </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 8 </td>\n   <td style=\"text-align:right;\"> 42 </td>\n   <td style=\"text-align:right;\"> 15 </td>\n   <td style=\"text-align:right;\"> 39 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Hermine et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 7 </td>\n   <td style=\"text-align:right;\"> 63 </td>\n   <td style=\"text-align:right;\"> 8 </td>\n   <td style=\"text-align:right;\"> 67 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Horby et al </td>\n   <td style=\"text-align:right;\"> DEXA </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 482 </td>\n   <td style=\"text-align:right;\"> 2104 </td>\n   <td style=\"text-align:right;\"> 1110 </td>\n   <td style=\"text-align:right;\"> 4321 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Lyngbakken et al </td>\n   <td style=\"text-align:right;\"> HCQ </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 1 </td>\n   <td style=\"text-align:right;\"> 27 </td>\n   <td style=\"text-align:right;\"> 1 </td>\n   <td style=\"text-align:right;\"> 26 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Recovery group </td>\n   <td style=\"text-align:right;\"> LOP+RIT </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 374 </td>\n   <td style=\"text-align:right;\"> 1616 </td>\n   <td style=\"text-align:right;\"> 767 </td>\n   <td style=\"text-align:right;\"> 3424 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Rohmani </td>\n   <td style=\"text-align:right;\"> INT-B </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 2 </td>\n   <td style=\"text-align:right;\"> 33 </td>\n   <td style=\"text-align:right;\"> 6 </td>\n   <td style=\"text-align:right;\"> 33 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Rosas et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 58 </td>\n   <td style=\"text-align:right;\"> 294 </td>\n   <td style=\"text-align:right;\"> 28 </td>\n   <td style=\"text-align:right;\"> 144 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Salama et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 26 </td>\n   <td style=\"text-align:right;\"> 249 </td>\n   <td style=\"text-align:right;\"> 11 </td>\n   <td style=\"text-align:right;\"> 128 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Salvarini et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 2 </td>\n   <td style=\"text-align:right;\"> 60 </td>\n   <td style=\"text-align:right;\"> 1 </td>\n   <td style=\"text-align:right;\"> 66 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Solidarity trial-LR </td>\n   <td style=\"text-align:right;\"> LOP+RIT </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 148 </td>\n   <td style=\"text-align:right;\"> 1399 </td>\n   <td style=\"text-align:right;\"> 146 </td>\n   <td style=\"text-align:right;\"> 1372 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Solidarity trial - HCQ </td>\n   <td style=\"text-align:right;\"> HCQ </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 104 </td>\n   <td style=\"text-align:right;\"> 947 </td>\n   <td style=\"text-align:right;\"> 84 </td>\n   <td style=\"text-align:right;\"> 906 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Solidarity trial - Interferon </td>\n   <td style=\"text-align:right;\"> INT-B </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 243 </td>\n   <td style=\"text-align:right;\"> 2050 </td>\n   <td style=\"text-align:right;\"> 216 </td>\n   <td style=\"text-align:right;\"> 2050 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Solidarity trial - Remdesivir </td>\n   <td style=\"text-align:right;\"> REM </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 301 </td>\n   <td style=\"text-align:right;\"> 2743 </td>\n   <td style=\"text-align:right;\"> 303 </td>\n   <td style=\"text-align:right;\"> 2708 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Spinner et al </td>\n   <td style=\"text-align:right;\"> REM </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 5 </td>\n   <td style=\"text-align:right;\"> 396 </td>\n   <td style=\"text-align:right;\"> 4 </td>\n   <td style=\"text-align:right;\"> 200 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Stone et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 9 </td>\n   <td style=\"text-align:right;\"> 161 </td>\n   <td style=\"text-align:right;\"> 3 </td>\n   <td style=\"text-align:right;\"> 82 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Tomazini et al </td>\n   <td style=\"text-align:right;\"> DEXA </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 85 </td>\n   <td style=\"text-align:right;\"> 151 </td>\n   <td style=\"text-align:right;\"> 91 </td>\n   <td style=\"text-align:right;\"> 148 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Ulrich et al </td>\n   <td style=\"text-align:right;\"> HCQ </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 13 </td>\n   <td style=\"text-align:right;\"> 67 </td>\n   <td style=\"text-align:right;\"> 6 </td>\n   <td style=\"text-align:right;\"> 61 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Veiga et al </td>\n   <td style=\"text-align:right;\"> TOCI </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 14 </td>\n   <td style=\"text-align:right;\"> 65 </td>\n   <td style=\"text-align:right;\"> 6 </td>\n   <td style=\"text-align:right;\"> 64 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Wang et al </td>\n   <td style=\"text-align:right;\"> REM </td>\n   <td style=\"text-align:right;\"> STD </td>\n   <td style=\"text-align:right;\"> 22 </td>\n   <td style=\"text-align:right;\"> 158 </td>\n   <td style=\"text-align:right;\"> 10 </td>\n   <td style=\"text-align:right;\"> 78 </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n### Network meta-analysis\nBelow, we conduct a random effects network meta-analysis where we consider \nstandard care (`treat = \"STD\"`) as the control treatment.\n\n\n::: {.cell hash='chapter_10_cache/html/unnamed-chunk-10_192eae6eb8c9553baa2da05ab618fd72'}\n\n```{.r .cell-code}\nNMA.covid <- netmeta(TE = TE, seTE = seTE, treat1 = treat1, treat2 = treat2,\n                     studlab = studlab, data = covid, sm = \"OR\", ref = \"STD\",\n                     comb.random = TRUE)\nsummary(NMA.covid)\n```\n\n::: {.cell-output .cell-output-stdout}\n```\nOriginal data:\n\n                               treat1 treat2      TE   seTE\nAbd-Elsalam et al                 HCQ    STD  0.1933 0.6233\nBiegel et al                      REM    STD -0.3484 0.1851\nCao et al                     LOP+RIT    STD -0.3390 0.3442\nCavalcanti et al                  HCQ    STD  0.0269 1.4174\nDavoudi-Monfared                INT-B    STD -0.9769 0.5126\nHermine et al                     STD   TOCI  0.0813 0.5501\nHorby et al                      DEXA    STD -0.1512 0.0625\nLyngbakken et al                  HCQ    STD -0.0392 1.4417\nRecovery group                LOP+RIT    STD  0.0422 0.0718\nRohmani                         INT-B    STD -1.2368 0.8579\nRosas et al                       STD   TOCI -0.0180 0.2565\nSalama et al                      STD   TOCI -0.2152 0.3774\nSalvarini et al                   STD   TOCI -0.8071 1.2380\nSolidarity trial-LR           LOP+RIT    STD -0.0066 0.1234\nSolidarity trial - HCQ            HCQ    STD  0.1883 0.1547\nSolidarity trial - Interferon   INT-B    STD  0.1326 0.0992\nSolidarity trial - Remdesivir     REM    STD -0.0219 0.0863\nSpinner et al                     REM    STD -0.4674 0.6765\nStone et al                       STD   TOCI -0.4442 0.6809\nTomazini et al                   DEXA    STD -0.2148 0.2355\nUlrich et al                      HCQ    STD  0.7915 0.5294\nVeiga et al                       STD   TOCI -0.9759 0.5244\nWang et al                        REM    STD  0.0953 0.4093\n\nNumber of treatment arms (by study):\n                              narms\nAbd-Elsalam et al                 2\nBiegel et al                      2\nCao et al                         2\nCavalcanti et al                  2\nDavoudi-Monfared                  2\nHermine et al                     2\nHorby et al                       2\nLyngbakken et al                  2\nRecovery group                    2\nRohmani                           2\nRosas et al                       2\nSalama et al                      2\nSalvarini et al                   2\nSolidarity trial-LR               2\nSolidarity trial - HCQ            2\nSolidarity trial - Interferon     2\nSolidarity trial - Remdesivir     2\nSpinner et al                     2\nStone et al                       2\nTomazini et al                    2\nUlrich et al                      2\nVeiga et al                       2\nWang et al                        2\n\nResults (common effects model):\n\n                               treat1 treat2     OR           95%-CI    Q\nAbd-Elsalam et al                 HCQ    STD 1.2570 [0.9498; 1.6635] 0.00\nBiegel et al                      REM    STD 0.9240 [0.7956; 1.0732] 2.12\nCao et al                     LOP+RIT    STD 1.0184 [0.9035; 1.1480] 1.08\nCavalcanti et al                  HCQ    STD 1.2570 [0.9498; 1.6635] 0.02\nDavoudi-Monfared                INT-B    STD 1.0786 [0.8922; 1.3039] 4.22\nHermine et al                     STD   TOCI 0.8147 [0.5761; 1.1523] 0.27\nHorby et al                      DEXA    STD 0.8560 [0.7605; 0.9636] 0.00\nLyngbakken et al                  HCQ    STD 1.2570 [0.9498; 1.6635] 0.03\nRecovery group                LOP+RIT    STD 1.0184 [0.9035; 1.1480] 0.11\nRohmani                         INT-B    STD 1.0786 [0.8922; 1.3039] 2.34\nRosas et al                       STD   TOCI 0.8147 [0.5761; 1.1523] 0.53\nSalama et al                      STD   TOCI 0.8147 [0.5761; 1.1523] 0.00\nSalvarini et al                   STD   TOCI 0.8147 [0.5761; 1.1523] 0.24\nSolidarity trial-LR           LOP+RIT    STD 1.0184 [0.9035; 1.1480] 0.04\nSolidarity trial - HCQ            HCQ    STD 1.2570 [0.9498; 1.6635] 0.07\nSolidarity trial - Interferon   INT-B    STD 1.0786 [0.8922; 1.3039] 0.33\nSolidarity trial - Remdesivir     REM    STD 0.9240 [0.7956; 1.0732] 0.44\nSpinner et al                     REM    STD 0.9240 [0.7956; 1.0732] 0.33\nStone et al                       STD   TOCI 0.8147 [0.5761; 1.1523] 0.12\nTomazini et al                   DEXA    STD 0.8560 [0.7605; 0.9636] 0.06\nUlrich et al                      HCQ    STD 1.2570 [0.9498; 1.6635] 1.13\nVeiga et al                       STD   TOCI 0.8147 [0.5761; 1.1523] 2.16\nWang et al                        REM    STD 0.9240 [0.7956; 1.0732] 0.18\n                              leverage\nAbd-Elsalam et al                 0.05\nBiegel et al                      0.17\nCao et al                         0.03\nCavalcanti et al                  0.01\nDavoudi-Monfared                  0.04\nHermine et al                     0.10\nHorby et al                       0.93\nLyngbakken et al                  0.01\nRecovery group                    0.72\nRohmani                           0.01\nRosas et al                       0.48\nSalama et al                      0.22\nSalvarini et al                   0.02\nSolidarity trial-LR               0.25\nSolidarity trial - HCQ            0.85\nSolidarity trial - Interferon     0.95\nSolidarity trial - Remdesivir     0.78\nSpinner et al                     0.01\nStone et al                       0.07\nTomazini et al                    0.07\nUlrich et al                      0.07\nVeiga et al                       0.11\nWang et al                        0.03\n\nResults (random effects model):\n\n                               treat1 treat2     OR           95%-CI\nAbd-Elsalam et al                 HCQ    STD 1.2570 [0.9498; 1.6635]\nBiegel et al                      REM    STD 0.9240 [0.7956; 1.0732]\nCao et al                     LOP+RIT    STD 1.0184 [0.9035; 1.1480]\nCavalcanti et al                  HCQ    STD 1.2570 [0.9498; 1.6635]\nDavoudi-Monfared                INT-B    STD 1.0786 [0.8922; 1.3039]\nHermine et al                     STD   TOCI 0.8147 [0.5761; 1.1523]\nHorby et al                      DEXA    STD 0.8560 [0.7605; 0.9636]\nLyngbakken et al                  HCQ    STD 1.2570 [0.9498; 1.6635]\nRecovery group                LOP+RIT    STD 1.0184 [0.9035; 1.1480]\nRohmani                         INT-B    STD 1.0786 [0.8922; 1.3039]\nRosas et al                       STD   TOCI 0.8147 [0.5761; 1.1523]\nSalama et al                      STD   TOCI 0.8147 [0.5761; 1.1523]\nSalvarini et al                   STD   TOCI 0.8147 [0.5761; 1.1523]\nSolidarity trial-LR           LOP+RIT    STD 1.0184 [0.9035; 1.1480]\nSolidarity trial - HCQ            HCQ    STD 1.2570 [0.9498; 1.6635]\nSolidarity trial - Interferon   INT-B    STD 1.0786 [0.8922; 1.3039]\nSolidarity trial - Remdesivir     REM    STD 0.9240 [0.7956; 1.0732]\nSpinner et al                     REM    STD 0.9240 [0.7956; 1.0732]\nStone et al                       STD   TOCI 0.8147 [0.5761; 1.1523]\nTomazini et al                   DEXA    STD 0.8560 [0.7605; 0.9636]\nUlrich et al                      HCQ    STD 1.2570 [0.9498; 1.6635]\nVeiga et al                       STD   TOCI 0.8147 [0.5761; 1.1523]\nWang et al                        REM    STD 0.9240 [0.7956; 1.0732]\n\nNumber of studies: k = 23\nNumber of pairwise comparisons: m = 23\nNumber of treatments: n = 7\nNumber of designs: d = 6\n\nCommon effects model\n\nTreatment estimate (sm = 'OR', comparison: other treatments vs 'STD'):\n            OR           95%-CI     z p-value\nDEXA    0.8560 [0.7605; 0.9636] -2.57  0.0101\nHCQ     1.2570 [0.9498; 1.6635]  1.60  0.1097\nINT-B   1.0786 [0.8922; 1.3039]  0.78  0.4346\nLOP+RIT 1.0184 [0.9035; 1.1480]  0.30  0.7649\nREM     0.9240 [0.7956; 1.0732] -1.04  0.3006\nSTD          .                .     .       .\nTOCI    1.2274 [0.8678; 1.7359]  1.16  0.2467\n\nRandom effects model\n\nTreatment estimate (sm = 'OR', comparison: other treatments vs 'STD'):\n            OR           95%-CI     z p-value\nDEXA    0.8560 [0.7605; 0.9636] -2.57  0.0101\nHCQ     1.2570 [0.9498; 1.6635]  1.60  0.1097\nINT-B   1.0786 [0.8922; 1.3039]  0.78  0.4346\nLOP+RIT 1.0184 [0.9035; 1.1480]  0.30  0.7649\nREM     0.9240 [0.7956; 1.0732] -1.04  0.3006\nSTD          .                .     .       .\nTOCI    1.2274 [0.8678; 1.7359]  1.16  0.2467\n\nQuantifying heterogeneity / inconsistency:\ntau^2 = 0; tau = 0; I^2 = 0% [0.0%; 50.0%]\n\nTests of heterogeneity (within designs) and inconsistency (between designs):\n                    Q d.f. p-value\nTotal           15.83   17  0.5358\nWithin designs  15.83   17  0.5358\nBetween designs  0.00    0      --\n```\n:::\n:::\n",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-in-header": [
        "<script src=\"site_libs/kePrint-0.0.1/kePrint.js\"></script>\r\n<link href=\"site_libs/lightable-0.0.1/lightable.css\" rel=\"stylesheet\" />\r\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}